Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib versus methotrexate for vulvar lichen planus
ACTRN12623000682640Phase 2Recruiting
- Sponsor
- Dr Rebecca Bronwyn Saunderson
- Start
- Apr 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deucravacitinib, methotrexate and betamethasone dipropionate in vulvar lichen planus (VLP) (3 arms), sponsored by Dr Rebecca Bronwyn Saunderson. Primary endpoint: Primary efficacy endpoint. Started Apr 2024; status: recruiting.
02
Drugs
deucravacitinibmethotrexatebetamethasone dipropionate
03
Conditions
vulvar lichen planus (VLP)
Beyond the preview
Go deeper on ACTRN12623000682640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000682640.